SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189
SynAct ("SynAct") announces that the company has received approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority to conduct the company’s Phase IIa study with the drug candidate AP1189. SynAct also announces that an application for clinical trial has been filed to the Norwegian Medicines Agency and Norwegian National Committee for Medical and Health Research Ethics.The Study is currently ongoing on clinical sites in Denmark following approval by the Danish Medicines Agency in June 2019. With the approval by the Swedish Medical Product Agency, patients can